 This study found that certain immunosuppressive treatments such as Rituximab may reduce the efficacy of COVID-19 vaccines in patients with autoimmune rheumatic diseases. Additionally, older patients and those who received their first vaccination within a short timeframe had lower antibody responses than those who did not receive any immunosuppressive treatment or were younger. Furthermore, the use of the experimental vaccine AZ-1222 was also linked to decreased antibody responses. To ensure optimal protection from COVID-19, it is important to consider these findings when administering vaccines to patients with autoimmune rheumatic diseases. This article was authored by Tatjana Schwarz, Godrudiga Burmester, Florian Korf, and others.